Latest Research

How long did patients stay on the Juniper AU program and why did they stop?

Peer-reviewed research reveals patient adherence to Juniper’s digital weight loss program in Australia

Published in the Journal of Community Medicine & Public Health
Authored by
Dr Louis Talay
Dr Matthew Vickers
Last updated
6
June
,
2024
5 min read

Key takeaways

Juniper’s adherence rate

Previous real-world research suggested that patients on Juniper’s platform in Australia were more likely to lose weight than clinical trials using the same medication.

However to gain a more accurate understanding of how effective Juniper’s digital weight loss program really is, it’s important to understand how long patients remained on Juniper’s program, and why they discontinued treatment.

Patients stayed on the program, on average, for 171 days

A dedicated adherence study published in the Journal of Behavioural Sciences indicates that patients stayed on the Juniper program, on average, for 171 days. The two most common reasons for discontinuing the program were  medication supply issues (43.7%) and the high cost of the program (26.2%).

Data was taken from self-directed, non-incentivised patients. Unlike clinical trials, in which participants do not have to pay for treatment, this was a real-world study.

Understanding patient adherence

  • This is the first peer-reviewed study to measure the adherence rate of an Australian digital weight loss service
  • The Juniper program is designed to give patients the tools they need to succeed, however adherence to our recommended program is not mandatory
  • This study was entirely comprised of self-directed, non-incentivised patients
  • As stock availability of these treatments improves, patient adherence to Juniper’s comprehensive, multidisciplinary program should improve

Key reasons for discontinuation

  • Inadequate supply of preferred medication (43.7%)
  • Program cost (26.2%),
  • Result dissatisfaction (9.9%)
  • Service dissatisfaction (7.2%)

Why we did this research

In order to continue improving our program, we wanted to better understand exactly how long the average patient stayed on Juniper’s program and what barriers they experienced to continuing treatment.

We’re committed to transparently publishing our data so that we can continue to improve our program.

Medically reviewed by

Dr Louis Talay

Medical Research Lead | Eucalyptus

Dr Matthew Vickers

Clinical Director | Eucalyptus

Explore more research

Juniper AU
 •
Journal of Diabetes, Obesity and Metabolism
 •
L. Talay
M. Vickers

Juniper Australia patients outperform clinical trial outcomes in world-first study

February 21, 2024
Juniper AU
 •
Telemedicine Reports
 •
L. Talay
M. Vickers

Patient satisfaction with different health coaching approaches

July 5, 2024